{"id":"NCT01289990","sponsor":"Boehringer Ingelheim","briefTitle":"Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes","officialTitle":"A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2013-05","completion":"2013-05","firstPosted":"2011-02-04","resultsPosted":"2014-07-15","lastUpdate":"2014-07-15"},"enrollment":2705,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Sitagliptin 100mg","otherNames":[]},{"type":"DRUG","name":"BI 10773","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BI 10773 low (drug naive)","type":"EXPERIMENTAL"},{"label":"BI 10773 high (drug naive)","type":"EXPERIMENTAL"},{"label":"Placebo (drug naive)","type":"PLACEBO_COMPARATOR"},{"label":"Sitagliptin 100mg (drug naive)","type":"ACTIVE_COMPARATOR"},{"label":"BI 10773 low (pioglitazone)","type":"EXPERIMENTAL"},{"label":"BI 10773 high (pioglitazone)","type":"EXPERIMENTAL"},{"label":"Placebo (pioglitazone)","type":"PLACEBO_COMPARATOR"},{"label":"BI 10773 low (metformin)","type":"EXPERIMENTAL"},{"label":"BI 10773 high (metformin)","type":"EXPERIMENTAL"},{"label":"Placebo (metformin)","type":"PLACEBO_COMPARATOR"},{"label":"BI 10773 low (metformin+sulfonylurea)","type":"EXPERIMENTAL"},{"label":"BI 10773 high (metformin+sulfonylurea)","type":"EXPERIMENTAL"},{"label":"Placebo (metformin+sulfonylurea)","type":"PLACEBO_COMPARATOR"}],"summary":"This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.","primaryOutcome":{"measure":"Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of Treatment","timeFrame":"Baseline and 52 weeks","effectByArm":[{"arm":"BI 10773 Low (Drug Naive)","deltaMin":-0.7,"sd":0.05},{"arm":"BI 10773 High (Drug Naive)","deltaMin":-0.82,"sd":0.05},{"arm":"Placebo (Drug Naive)","deltaMin":0.09,"sd":0.05},{"arm":"Sitagliptin 100mg (Drug Naive)","deltaMin":-0.58,"sd":0.05},{"arm":"BI 10773 Low (Pioglitazone)","deltaMin":-0.63,"sd":0.07},{"arm":"BI 10773 High (Pioglitazone)","deltaMin":-0.71,"sd":0.07},{"arm":"Placebo (Pioglitazone)","deltaMin":-0.03,"sd":0.07},{"arm":"BI 10773 Low (Metformin)","deltaMin":-0.69,"sd":0.05},{"arm":"BI 10773 High (Metformin)","deltaMin":-0.76,"sd":0.05},{"arm":"Placebo (Metformin)","deltaMin":-0.07,"sd":0.05},{"arm":"BI 10773 Low (Metformin+Sulfonylurea)","deltaMin":-0.78,"sd":0.05},{"arm":"BI 10773 High (Metformin+Sulfonylurea)","deltaMin":-0.74,"sd":0.05},{"arm":"Placebo (Metformin+Sulfonylurea)","deltaMin":-0.04,"sd":0.05}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"0.1245"},{"comp":"OG001 vs OG003","p":"0.0022"},{"comp":"OG004 vs OG006","p":"<0.0001"},{"comp":"OG005 vs OG006","p":"<0.0001"},{"comp":"OG007 vs OG009","p":"<0.0001"},{"comp":"OG008 vs OG009","p":"<0.0001"},{"comp":"OG010 vs OG012","p":"<0.0001"},{"comp":"OG011 vs OG012","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":243,"countries":["United States","Belgium","Canada","China","France","Germany","Greece","India","Ireland","Japan","Mexico","Philippines","Slovakia","Slovenia","South Korea","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["35472672","33084149","28753486","26701110","26324220"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":229},"commonTop":["Hyperglycaemia","Nasopharyngitis","Urinary tract infection","Upper respiratory tract infection","Hypoglycaemia"]}}